| scholarly article | Q13442814 |
| P50 | author | Lynne Mofenson | Q43882680 |
| Brooks Jackson | Q56883534 | ||
| P2093 | author name string | M Mirochnick | |
| F Mmiro | |||
| M G Fowler | |||
| P Musoke | |||
| L A Guay | |||
| G Becker-Pergola | |||
| M Mracna | |||
| S H Eshleman | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Uganda | Q1036 |
| nevirapine | Q263713 | ||
| vertical transmission | Q2834381 | ||
| HIV | Q15787 | ||
| HIV transmission | Q49029021 | ||
| P304 | page(s) | F111-5 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission | |
| P478 | volume | 14 |
| Q36467686 | (C2) Saliva, breast milk, and mucosal fluids in HIV transmission |
| Q35742512 | A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies |
| Q95326815 | A single variant sequencing method for sensitive and quantitative detection of HIV-1 minority variants |
| Q28534423 | Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study |
| Q36223812 | Adherence to antiretroviral therapy: an update of current concepts |
| Q28477379 | Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa |
| Q33958977 | Advances and research directions in the prevention of mother-to-child HIV-1 transmission |
| Q35673592 | Advances in prevention of mother-to-child HIV transmission |
| Q34087809 | Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy |
| Q45722783 | Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel |
| Q34346305 | Antiretroviral therapy in pregnancy: a focus on safety |
| Q34494986 | Antiretroviral treatment for children with peripartum nevirapine exposure |
| Q33722976 | Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa |
| Q37338979 | Antiviral strategies |
| Q53851252 | British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). |
| Q37730522 | Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors |
| Q42254682 | Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients |
| Q37037070 | Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission |
| Q36811249 | Clinical implications of HIV-1 minority variants |
| Q34338893 | Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227 |
| Q34489239 | Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. |
| Q40674710 | Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants |
| Q33739249 | Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission |
| Q43497062 | Editorial: giving antiretrovirals in the peripartum period to prevent mother-to-child HIV transmission in low-income countries: only a short-term stopgap measure |
| Q77697505 | Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies |
| Q37207234 | Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda |
| Q34071112 | Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine |
| Q38884501 | Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial |
| Q36776545 | Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission |
| Q34110204 | Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. |
| Q33906239 | Genotypic testing for human immunodeficiency virus type 1 drug resistance |
| Q35960319 | German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008 |
| Q53991841 | Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. |
| Q34710280 | HIV-1/AIDS and maternal and child health in Africa |
| Q37245203 | Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. |
| Q34081115 | Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C. |
| Q38882753 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. |
| Q93122212 | Linked dual-class HIV resistance mutations are associated with treatment failure |
| Q36060517 | Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment |
| Q38883500 | Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries |
| Q34471322 | Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies |
| Q35917412 | Nevirapine in the treatment of HIV. |
| Q83676850 | Nevirapine-based therapy after suppression: can we switch? |
| Q73591243 | Nevirapine: an option for preventing as well as treating paediatric HIV infection |
| Q34078483 | Nevirapine: pharmacokinetic considerations in children and pregnant women |
| Q34574291 | Options for prevention of HIV transmission from mother to child, with a focus on developing countries |
| Q34876113 | Pediatric HIV infection and treatment |
| Q33605273 | Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy |
| Q38047214 | Pharmacokinetic optimization of antiretroviral therapy in pregnancy. |
| Q35557216 | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| Q82307179 | Phenotypic analysis of HIV-1 genotypic drug-resistant isolates from China, using a single-cycle system |
| Q36683440 | Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children |
| Q36290009 | Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure |
| Q34483505 | Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates |
| Q38865904 | Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns |
| Q37115730 | Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates |
| Q46261840 | Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). |
| Q24792802 | Pre-exposure chemoprophylaxis for HIV: it is time |
| Q40512553 | Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy |
| Q37216229 | Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa |
| Q36833511 | Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis |
| Q42726281 | Preventing HIV infection |
| Q35598505 | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. |
| Q46079196 | Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China |
| Q35947480 | Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies |
| Q35145366 | Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission |
| Q35108735 | Supervised interruptions of antiretroviral therapy |
| Q37018369 | The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. |
| Q30425595 | The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART. |
| Q34425821 | The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection |
| Q22241890 | The spread, treatment, and prevention of HIV-1: evolution of a global pandemic |
| Q45035066 | Therapeutic strategies for HIV infection: early response to antiretroviral treatment, predictive factor for the longer term response |
| Q40783234 | Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles |
| Q35610798 | Treatment of antiretroviral-drug-resistant HIV-1 infection |
| Q36557330 | Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities |
| Q34749066 | Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection |
| Q74021275 | [Medically assisted reproduction and the desire for a child by HIV infected couples: has the time for a change in attitude come?]] |
| Q77363100 | [Prevention of vertical transmission and treatment of infection caused by the human immunodeficiency virus in the pregnant woman. Recommendations of the Study Group for AIDS, Infectious Diseases, and Clinical Microbiology, the Spanish Pediatric Asso |
Search more.